Cytogenetics in the management of B-cell acute lymphoblastic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)

• Published in: Current research in translational medicine 2023-10, Vol.71 (4), p.103434-103434, Article 103434
• Main Authors: Tueur, Giulia, Quessada, Julie, De Bie, Jolien, Cuccuini, Wendy, Toujani, Saloua, Lefebvre, Christine, Luquet, Isabelle, Michaux, Lucienne, Lafage-Pochitaloff, Marina
• Format: Article
• Language: English
• Subjects: B-cell acute lymphoblastic leukemia; Cytogenetic Analysis - methods; Cytogenetics; Cytogenomics; Hematology; Humans; ICC classification; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Societies, Medical; WHO classification
• ISSN: 2452-3186; 2452-3186
• DOI: 10.1016/j.retram.2023.103434

Cytogenetic analysis is mandatory at initial assessment of B-cell acute lymphoblastic leukemia (B-ALL) due to its diagnostic and prognostic value. Results from chromosome banding analysis and complementary FISH are taken into account in therapeutic protocols and further completed by other techniques (RT-PCR, SNP-array, MLPA, NGS, OGM). Indeed, new genomic entities have been identified by NGS, mostly RNA sequencing, such as Ph-like ALL that can benefit from targeted therapy. Here, we have attempted to establish cytogenetic guidelines by reviewing the most recent published data including the novel 5th World Health Organization and International Consensus Classifications. We also focused on newly described cytogenomic entities and indicate alternative diagnostic tools such as NGS technology, as its importance is vastly increasing in the diagnostic setting.